careers product portfolio product portfolio commercial late stage eflapegrastim spi 2012 qapzola apaziquone development poziotinib out licensing glossary product returns evomela product returns folotyn product returns marqibo product returns zevalin product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings 10k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stock split history analyst coverage ownership profile investor faqs patient information patient assistance star colorectal cancer non hodgkin s lymphoma acute lymphoblastic leukemia peripheral t cell lymphoma osteosarcoma medical professionals medical professionals clinical trials grants investigator initiated trials careers contact us our commitment to patients spectrum s core mission is to bring pharmaceutical products to patients for unmet medical needs . to this mission we bring our years of drug development expertise coupled with the insight of working in many different oncology indications . learn more our products spectrum and its subsidiaries have six marketed oncology hematology products three for different types of non hodgkins lymphoma one for advanced metastatic colorectal cancer one for a certain type of acute lymphoblastic leukemia all and one for multiple myeloma . there are two products in late stage development as well as a broad and diversified portfolio of proprietary drugs in various stages of development all with a focus on oncology and hematology . learn more company highlights fda advisory committee votes that qapzola apaziquone has not shown substantial evidence of a treatment effect over placebowednesday september 14 2016 spectrum pharmaceuticals reports second quarter 2016 financial results and pipeline updatetuesday august 9 2016 spectrum pharmaceuticals announces second quarter 2016 financial results teleconference and webcasttuesday august 2 2016 expanding patient options our passion to deliver additional options for patients suffering from cancer is behind every action we take . we will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes . learn more about the spectrum philosophy . latest corporate presentation click here or on the image below to view our current corporate presentation . our company company philosophy partnerships management board of directors careers product portfolio commercial late stagedevelopment out licensing glossary investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs patient information patient assistance star colorectal cancer non hodgkin s lymphoma acute lymphoblastic leukemia peripheral t cell lymphoma osteosarcoma medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forward looking statements within the meaning of section 27a of the securities act of 1933 as amended and section 21e of the securities exchange act of 1934 as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of 1995 . such forward looking statements are based on the beliefs of the company s management as well as assumptions made by and information currently available to the company s management . readers should not put undue reliance on these forward looking statements . forward looking statements are inherently subject to risks and uncertainties some of which can not be predicted or quantified . spectrum pharmaceuticals inc. s actual results may differ materially from the results projected in the forward looking statements . factors that might cause such a difference include but are not limited to those discussed in the company s most recent form 10 k and 10 qs . we do not plan to update any such forward looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law . all contents copyright spectrum pharmaceuticals inc. 2016 . all rights reserved . pp all 00 0015 site map privacy policy terms of use linking policy contact us remote support clinical support webmail